Genaissance Report issue

Contributed to NME For profit Phase 3
Founded: New Haven CT United States (1997)
Status: Acquired by Clinical Data, Inc. (2005) → now AbbVie (2019)

Organization Overview

First Clinical Trial
2006
NCT00285376
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Genaissance Pharmaceuticals

Active Ingredients

Drugs in Phase 3 Trials (1)

vilazodone (viibryd) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1